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Background: Deep vein thrombosis (DVT) is a quality measure recorded by initiatives such as the National Surgical
Quality Improvement Program (NSQIP). However, because surveillance-detected DVT rates may be higher than
symptomatic DVT rates, we examined how differences in the method of DVT detection may affect the use of this quality
measure.
Methods: Using the NSQIP database (2007-2009), we compared DVT rates of vascular (amputation, open aortic
procedures, and lower extremity bypass) and nonvascular (prostatectomy, gastric bypass [GBP], and hip arthroplasty)
operations. Using a predefined literature search strategy, we compared the incidence of DVT in NSQIP to the incidence
of DVT reported in published literature, diagnosed by symptomatic status or by surveillance studies.
Results:Within NSQIP, the overall incidence of postoperative DVT was 0.7%. This varied from 0.3% after GBP to 1.8%
after open aortic surgery. Across all procedures except amputation, the incidence of DVT in NSQIP was similar to the
incidence of DVT reported in our literature survey of “symptomatic” DVTs. The relative rate (RR) of literature-derived
symptomatic DVTs to NSQIP ranged from 0.7 for aortic cases (95% confidence interval [CI], 0.3-1.7) to 1.4 (95% CI,
.7-3.1) for GBP. Overall, surveillance studies had 11.6 higher RR of DVT compared to NSQIP (95% CI, 10.5-13),
ranging from 2.6 for GBP (95% CI, 1.4-5) to 14 .5 for hip arthroplasty (95% CI, 10.5-20).
Conclusions: The incidence of DVT reported in NSQIP is similar to the reported incidence of symptomatic DVT for many
high-risk procedures but is much lower than rates of DVT reported in surveillance studies. Clear delineation of
symptomatic vs surveillance detection of DVTwould improve the usefulness of this measurement in quality improvement
registries. ( J Vasc Surg 2012;56:1045-51.)
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pDeep vein thrombosis (DVT) is an important compo-
nent of venous thromboembolism (VTE) and a major cause
of hospital-acquired morbidity and mortality. Therefore,
detection and prevention of VTE are the focus of several
patient safety initiatives such as the Agency for Healthcare
Research and Quality Patient Safety Indicators, American
Public Health Association’s Coalition to Prevent Deep
Vein Thrombosis, and the US Surgeon General’s Work-
shop on Deep Vein Thrombosis.1-3 For these reasons, DVT
is recorded in the American College of Surgeons (ACS)
National Surgical Quality Improvement Program (NSQIP)
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http://dx.doi.org/10.1016/j.jvs.2012.02.066s a postoperative complication and is considered to be an
mportant quality indicator in surgery.1
However, the manner in which a DVT is detected can
ramatically influence the apparent incidence of this com-
lication. It is well known that the use of screening proto-
ols increases the detection of DVT in high-risk popula-
ions. For example, institutions with aggressive screening
rograms have reported higher DVT rates in the National
rauma Registry.4 This is not surprising, as up to 50% of
atients with DVT may not have specific symptoms.5 There-
ore, if the method of detection of DVT is not specified in data
egistries (screening-based vs symptom-based), any observed
ariation in DVT rates could potentially be due to differences
n the method of detection, rather than real differences in the
nderlying incidence of DVT.
To understand the potential magnitude of this effect,
e examined DVT rates in NSQIP across a broad variety of
rocedures. In NSQIP, DVT is defined as the identification
f new venous thrombus necessitating treatment within 30
ays of the index operation.6 This definition does not
pecifically delineate whether the DVT was detected using
creening vs symptomatic definitions. Potentially, hospitals
hat perform screening commonly could report high rates
f DVT in NSQIP, whereas hospitals that report only
ymptomatic DVT may report low rates in NSQIP. To
rovide context for screening and symptomatic DVT rates,
e compared the rates observed in NSQIP to a broad
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reported surgical cohorts.
METHODS
NSQIP dataset and study population. The ACS
NSQIP is a multi-institutional database of patients under-
going surgery within 330 participating hospitals across the
United States. Data are recorded on preoperative, opera-
tive, and postoperative patient-level variables, including
in-hospital or 30-day mortality and morbidity after the
index procedure. Participant hospitals are provided risk-
adjusted outcomes for quality improvement (QI) purposes.
Data abstraction and variable definitions are available from
the ACS NSQIP Web site.6
In our study, we sought to examine a broad spectrum
of vascular and nonvascular surgical procedures whose pa-
tients were at measurable risk for DVT. Therefore, we
studied patients who underwent open aortic surgery, lower
extremity bypass (LEB), major amputation (above ankle,
below knee, or above knee), prostatectomy, hip arthro-
plasty, and bariatric gastric bypass (GBP) surgery using the
ACS NSQIP Participant Use File for 2007-2009. Cases
were identified by primary procedural Current Procedural
Terminology codes (Appendix A, online only).
Definition of DVT in NSQIP. The goal of our proj-
ect was to examine the incidence of DVT after these pro-
cedures and to compare these rates to known screening and
symptomatic rates of DVT. In NSQIP, DVT is recorded
using three variables (the occurrence of a DVT or phlebitis,
the number of events, and days to the occurrence of the
DVT/phlebitis; Appendix B, online only). DVT/phlebitis
is defined as the “identification of a new blood clot or
thrombus within the venous system, which may be coupled
with inflammation within 30 days of the operation. This
diagnosis is confirmed by a duplex ultrasound scan, veno-
gram, or computed tomography scan.”6
Defining the rate of DVT in screening and symp-
tomatic populations. Using a predefined search strategy,
Medline (1950-present, last searched March 2010) was
queried to determine the incidence of DVT after each
selected operation. Medical subject heading terms or key
words for each operation (such as “prostatectomy”) and
the medical subject heading term “venous thrombosis”
were used, and the Boolean term “AND” was used to find
their intersection. Additional articles were also identified by
key references.
Inclusion criteria required that the article report the
total number of adult (18 years of age) patients undergo-
ing one of the prespecified operations as well as report a
postoperative DVT rate verified by venography or duplex
ultrasound scan. Studies using fibrinogen required confir-
mation venogram or ultrasound scan. Exclusion criteria
included publication before 1990 (to reflect contemporary
practice), phase I or II drug study, or publication in lan-
guages other than English.
Articles were screened and reviewed, and the number of
patients undergoing each operation was recorded. Symp-
tomatic DVT rate was calculated as the number of patients rith a DVT and symptoms divided by the total number of
atients undergoing the surgery in a series reporting symp-
om status. Similarly, the screening DVT rate was calcu-
ated as the total number of DVTs (irrespective or symp-
omatic status) detected via screening, divided by the total
umber of patients undergoing surgery. Calf DVTs were
ncluded, based on current guidelines supporting the treat-
ent of calf DVT due to propagation and pulmonary
mbolism risk in postsurgical patients.7 Pooled estimates of
he incidence of total DVT and symptomatic DVT were
hen calculated for each operation.
Main analysis: comparison of DVT rate in NSQIP
ith screening and symptomatic DVT studies. Our
ain outcome measure was the relative rate (RR) of DVT
n symptomatic and surveillance series compared to the
SQIP DVT rate for each operation. This rate was derived
y comparing the rates of surveillance and symptomatic
VTs, as defined above, by the DVT rate in NSQIP for
ach operation (Fig 1). Additionally, rates of DVT in
SQIP and our literature review were evaluated as propor-
ions and their rates were compared with 2 statistic. All
nalyses were performed with Stata Release 11 (STATA
orp, College Station, Tex). Probability values .05 were
onsidered statistically significant.
This study was deemed exempt from institutional re-
iew board review by the Dartmouth College Committee
or the Protection of Human Subjects due to the de-
dentified nature of the ACS NSQIP data.
ESULTS
Incidence of DVT in NSQIP. From 2007 to 2009,
e studied a total of 61,150 procedures in NSQIP, includ-
ng 8043 major amputations, 5181 aortic operations,
1,422 LEBs, 27,890 GBPs, 3087 prostatectomies, and
527 hip arthroplasties. The overall incidence of 30-day
VT across all of these procedures (n 61,150) was 0.7%.
owever, the incidence of DVT varied by operation. DVT
ates at 30 days were lowest in GBP (0.3%; 95% confidence
nterval [CI], 0.2%-0.3%) and highest in aortic cases (1.8%;
5% CI, 1.4%-2.1%; Table I).
Incidence of DVT in surveillance and symptomatic
tudies. Using our literature search strategy, we identified
92 potential articles. From these, we selected 44 series
ig 1. Analytical plan to compare National Surgical Quality Im-
rovement Program (NSQIP) deep vein thrombosis (DVT) rated
o a symptomatic and surveillance series of postoperative DVT.eporting DVT after surgical procedures (six amputa-
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Volume 56, Number 4 De Martino et al 1047tions,8-13 three LEBs,9,14,15 six aortic surgeries,9,14,16-19
eight prostatectomies,20-27 six GBPs,28-33 and 15 hip ar-
throplasties,34-48 as shown in Fig 2. Of these, 39 studies
(89%) reported surveillance DVT rates, and 35 studies
(79%) reported symptomatic DVT rates (Table II).
As expected, the incidence of DVT was higher in sur-
veillance studies than in symptomatic studies. Series report-
ing surveillance DVT rates encompassed data from 20,011
patients and reported an overall DVT rate of 8.3%. Symp-
tomatic studies, encompassing data from 27,248 patients,
reported an overall DVT rate that was significantly lower, at
0.7% (P  .001). Among surveillance studies, DVT rates
varied by operation, ranging from 0.8% for GBP (95% CI,
0.3%-1.2%) to 14.4% for amputation (95% CI, 10.8%-
18.1%). Similarly, across symptomatic studies, DVT rates
varied by operation, ranging from 0% for LEB to 5.3% for
amputation (95% CI, 2.6%-8%; Table II).
Comparison of surveillance and NSQIP DVT rates.
Across all procedures, the rate of surveillance-detected DVT
in literature series was significantly higher than the rate of
DVT in NSQIP (0.7% vs 8.3%; P  .001). By operation, we
found that for all procedures, surveillance DVT rates were
Table I. Comparison of surveillance and symptomatic seri
2009
Case
NSQIP
(mean, 95% CI)
Symptomatic
literature series
(mean, 95% CI)
Surve
series
Aortic cases 1.8% (1.4%-2.1%) 1.3% (0.2%-2.4%) 8.1%
LEB 0.9% (0.7%-1.1%) 0.0% (0%-0%) 4.7%
Amputation 1.3% (1%-1.5%) 5.3% (2.6%-8%) 14.4%
Prostatectomy 0.7% (0.4%-1%) 0.7% (0.5%-0.8%) 2.6%
Hip arthroplasty 0.7% (0.5%-0.9%) 0.7% (0.6%-0.8%) 9.7%
GBP 0.3% (0.2%-0.3%) 0.4% (0.1%-0.7%) 0.8%
CI, Confidence interval; GBP, gastric bypass; LEB, lower extremity bypass;
Surveillance relative rate surveillance rate/NSQIP rate.
Symptomatic relative rate symptomatic rate/NSQIP rate.
aNSQIP vs surveillance.
bNSQIP vs symptomatic.
Fig 2. Flow diagram of the literature search strategy to
deep venous thrombosis for each of six operations.
randomized controlled trial.significantly higher than NSQIP DVT rates (Table I). For sxample, the rate of DVT after aortic operations in surveil-
ance series was 8.1% (95% CI, 5.9%-10.3%) compared to 1.8%
95% CI, 1.4%-2.1%) within NSQIP (P .001).
Comparison of symptomatic and NSQIP DVT
ates. Across our entire cohort, the rate of symptomatic
VT in literature series was similar to the rate of DVT in
SQIP following all procedures (0.7% vs 0.7%; P  .70).
hen we compared the rates of symptomatic series and
SQIP by individual operation, we found that for all proce-
ures except amputation, symptomatic DVT rates were simi-
ar to NSQIP DVT rates (Table I). For example, the rate of
VT after aortic operations in symptomatic series was 1.3%
95% CI, 0.2%-2.4%) compared to 1.8% (95% CI, 1.4%-2.1%)
ithin NSQIP (P  .5). Within our amputation cohort, we
ound that the rate of DVT after major amputation in NSQIP
1.3%) was much lower than published cohorts (5.3%) or
urveillance cohorts (14.4%; Table I).
Relative rates of DVT among surveillance or symp-
omatic compared to NSQIP series. Finally, we calcu-
ated the RRs of DVT in surveillance studies and NSQIP
nd then compared these rates to the RRs of DVT in
ymptomatic studies and NSQIP. Overall, surveillance
deep venous thrombosis compared to the NSQIP 2007-
e literature
n, 95% CI)
P
valuea
P
valueb
Symptomatic
RR (95% CI)
Surveillance
RR (95% CI)
%-10.3%) .001 .5 0.7 (0.3-1.7) 4.6 (3.3-6.5)
%-7.6%) .001 .4 0.0 5.1 (2.7-9.7)
.8%-18.1%) .001 .001 4.2 (2.4-7.3) 11.5 (8.4-15.8)
%-3.3%) .001 .9 1.0 (0.6-1.6) 3.6 (2.2-5.9)
%-10.2%) .001 .7 1.1 (0.7-1.5) 14.5 (10.5-20)
%-1.2%) .002 .4 1.4 (0.7-3.1) 2.6 (1.4-5)
P, National Quality Surgical Improvement Program; RR, relative risk.
ify symptomatic and surveillance series of postoperative
Gastric bypass; LEB, lower extremity bypass; RCT,es of
illanc
(mea
(5.9
(1.9
(10
(1.9
(9.2
(0.3
NSQIident
GBP,tudies had 11.6-fold higher RR of DVT compared to
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Study
Patients
Total
DVTsa
Symptomatic
DVTs
Surveillance
DVT rateb
Symptomatic
DVT ratec DiagnosisAortic surgery Study type
Farkas 199314 RCT 146 11 — 7.5% — Ultrasound, venogram
Olin 199319 Pros. cohort 50 9 0 18% 0% Venogram
Fletcher 19979 Pros. cohort 52 6 — 12% — Ultrasound
Killewich 199718 RCT 100 2 1 2% 1% Ultrasound
Eagleton 200217 Pros. cohort 50 3 2 6% 4% Ultrasound
de Maistre 200916 Pros. cohort 193 17 2 8.8% 1% Ultrasound
Total 591 48 5 8.1% 1.3%
Lower extremity bypass
Farkas 199314 RCT 87 3 — 3.4% — Ultrasound, venogram
Fletcher 19979 Pros. cohort 54 5 — 9.3% — Ultrasound
Passman 200015 Pros. cohort 71 2 0 2.8% 0% Ultrasound
Total 212 10 0 4.7% 0.0%
Amputation
Yaeger 19958 Pros. cohort 72 9 1 12.5% 1.4% Ultrasound
Fletcher 19979 Pros. cohort 21 3 — 14.3% — Ultrasound
Burke 200010 Pros. cohort 8 4 2 50% 25% Ultrasound
Lastória 200611 RCT 75 8 — 10.7% — Ultrasound
Bandeira 200812 Pros. cohort 128 12 2 9.4% 1.6% Ultrasound
Matielo 200813 Pros. cohort 56 16 9 28.6% 16.1% Ultrasound
Total 360 52 14 14.4% 4.9%
Prostatectomyd
Cisek 199322 Retro. cohort 1300 — 5 — 0.4% Ultrasound or
venogram
Leibovitch 199526 Pros. cohort 245 9 7 3.7% 3% Ultrasound
Kibbel 199724 Pros. cohort 158 5 0 3.2% 0% Ultrasound
Heinzer 199823 Retro. cohort 508 — 18 — 3.5% Ultrasound or
venogram
Augustin 200320 Retro. cohort 1243 13 — 1.0% — Ultrasound
Koya 200525 Retro. cohort 1364 — 3 — 0.2% Not provided
Secin 200827 Retro. cohort 5951 — 27 — 0.5% Venogram, ultrasound
and fibrinogen
Beyer 200921 Pros. cohort 411 26 8 6.3% 1.9% Ultrasound
Total 11,180 53 68 2.6% 0.7%
Hip arthroplastye
Hull 199340 RCT 665 148 8 22.3% 1.2% Venogram
Hamulyák 199539 RCT 191 54 0 28.3% 0% Venogram
Eriksson 199737 RCT 1587 338 6 21.3% 0.4% Venogram
Francis 199738 RCT 282 77 4 27.3% 1.4% Venogram
Manganelli 199843 RCT 61 10 4 16.4% 6.6% Venogram
Planès 199846 RCT 460 49 — 10.7% — Venogram
Planès 199945 RCT 440 92 5 20.9% 1.1% Venogram
Hull 200041 RCT 1011 161 30 15.9% 3.0% Venogram
Lassen 200242 RCT 1826 119 8 6.5% 0.4% Venogram
Turpie 200248 RCT 1584 114 11 7.2% 0.7% Venogram
Prandoni 200247 RCT 360 11 5 3.1% 1.4% Ultrasound
Pitto 200444 RCT 200 9 2 4.5% 1.0% Ultrasound
Eriksson 200634 RCT 873 82 3 9.4% 0.3% Venogram
Eriksson 200736 RCT 2651 159 16 6.0% 0.6% Venogram
Eriksson 200835 RCT 3153 65 4 2.1% 0.1% Venogram
Total 15,344 1488 106 9.7% 0.7%
Gastric bypass
Eriksson 199729 Retro. cohort 328 — 5 — 1.5% Venogram
Scholten 200232 Retro. cohort 481 3 1 0.6% 0.2% Ultrasound
Westling 200233 Pros. cohort 116 2 0 1.7% 0% Ultrasound
Prystowsky 200531 Pros. cohort 106 4 — 3.8% — Ultrasound
Brasileiro 200828 Pros. cohort 126 1 1 0.8% 0.8% Ultrasound
Escalante-Tattersfield 200830 Pros. cohort 618 1 0 0.2% 0% Ultrasound
Total 1775 11 7 0.8% 0.4%
DVT, Deep vein thrombosis; Pros., prospective; RCT, randomized controlled trial; Retro., retrospective.
aTotal DVTs represent all DVTs (symptomatic and asymptomatic) only for series performing surveillance studies.
bRate calculated as total DVTs over total patients in literature series performing surveillance DVT studies.
cRate calculated as number of symptomatic DVTs over total patients in literature series reporting symptomatic DVT.
dIncludes nonsurveillance cohorts due to limited number of available studies.
eLimited to RCTs only.
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Volume 56, Number 4 De Martino et al 1049NSQIP (95% CI, 10.5-13), ranging from 2.6 (GBP) to
14.5 (for hip arthroplasty; Table I). In contrast, the overall
RR of symptomatic DVT compared to NSQIP was approx-
imately one for all procedures (RR, 1.0; 95% CI, 0.9-1.2),
ranging from 0.7 for aortic cases (95% CI, 0.3-1.7) to 1.4
for GBP (95% CI, 0.7-3.1). One notable procedure was
lower extremity amputation, wherein the RR of DVT in
symptomatic studies compared with NSQIP studies was
4.2 (95% CI, 2.4-7.3). LEB series had no reported symp-
tomatic DVTs, prohibiting calculation of an RR.
DISCUSSION
Efforts to record and report the incidence of DVT are
ubiquitous among QI efforts in surgery, and ACS NSQIP,
the largest and most broadly utilized surgical QI program
in the United States, is no exception. Our study indicates
that the rate of DVT within ACS NSQIP is quite low, even
across a broad spectrum of major vascular and nonvascular
procedures. However, because of imprecision in the defini-
tion of DVT in NSQIP—wherein no discrimination is
made as to why the DVT was detected—it is difficult to
interpret the results reported in participating centers. In
other words, given current definitions, a hospital with a
high rate of DVT may represent a higher true incidence of
DVT or may represent the result of more aggressive screen-
ing protocols in high-risk populations, such as those with
contraindications to pharmacologic prophylaxis or those
with thrombotic risk factors.
The detection and prevention of VTE, and in particular
DVT, has become a matter of primary importance across
many efforts in a public awareness for patient safety.1-3,49
For example, The Agency for Healthcare Research and
Quality had named postoperative pulmonary embolism or
DVT as a patient safety indicator,1 and the most recent
American College of Chest Physicians Guidelines for DVT
prophylaxis places significant emphasis on QI initiatives for
hospitals to reduce VTE events.7 This has led to interest in
using VTE and prophylaxis strategies as a potential qualifier
for reimbursement to healthcare organizations.3
Surgeons, patients, and payers all agree that QI registries,
such as the ACS NSQIP, should carefully track VTE events in
postoperative surgical patients.1,3 This information is neces-
sary to compare interfacility and national complication rates
for local QI efforts and ensure that quality benchmarks are
achieved. However, variation exists in the manner in which
DVT is measured and recorded. As our study has outlined, the
incidence of DVT varies based on the type of operation and
the method of detection—screening vs symptomatic. Without
proper identification of how DVTs were identified, physicians
or institutions may be inappropriately labeled as having higher
DVT rates and could potentially incur inappropriate penalties
in the setting of a QI program that closely monitors the rate of
postoperative DVT. Based on our findings, surgeons who
liberally use postoperative DVT surveillance screening could
potentially have rates of DVT 2 to 14 times higher than the
NSQIP average.
Because understanding which rate, surveillance, or symp-
tomatic detected is a better quality measure is unknown, a dtraightforward solution toward improving the measurement
f DVT would be to record DVT events within QI registries
sing a variable to indicate if the DVT was symptomatic or
dentified on screening. This would lead to more accurate
eporting of DVT rates postoperatively and allow proper
omparison between surgeons and institutions. Further, it
ould aid in risk-adjustment methodology, allowing for more
recise estimates of DVT in high-risk populations. Finally, it
ould allow QI initiatives to accurately reward providers with
ow rates of DVT rather than penalizing those providers who
tilize screening protocols.
However, even if a simple solution exists, many will
rgue that a change in variable definition is not necessary.
or example, current American College of Chest Physician
uidelines recommend against postoperative screening for
VT in elective surgery, and therefore any “screening”
ould be unlikely in the populations studied in NSQIP.
owever, in two important groups, screening is recom-
ended: (1) high-risk populations and (2) those with
ontraindication to prophylaxis.7 There is measurable evi-
ence that these groups exist in NSQIP. First, many believe
hat screening is important in high-risk populations such as
eurosurgery,49-51 and neurosurgery patients are well rep-
esented within NSQIP. For example, in 2009, there were
ver 6000 neurosurgical operations recorded in ACS
SQIP, and neurosurgical patients had one of the highest
verall rates of DVT (1.2%). Furthermore, it is likely that
everal centers routinely screen these patients for DVT,
ecause, at present, several guidelines recommend screen-
ng neurosurgery patients because of their propensity for
VT.51-53 Second, another group of patients at risk for
VT in NSQIP are those patients who experience postop-
rative bleeding complications and therefore have a contra-
ndication to pharmacologic DVT prophylaxis. Within ACS
SQIP 2009, over 1400 postoperative bleeding complica-
ions requiring transfusion were reported across 387 oper-
tions. Therefore, this group represents a broadly distrib-
ted group of patients at high risk for DVT, and guidelines
upport DVT surveillance in this group. Therefore, while
rguments against instituting a variable change exist, there
re several easily imaginable settings wherein this simple
fix” could be beneficial.
Our study has several limitations. First, many studies
dentified in our literature search are over a decade old and
ay not represent current DVT rates. The exact effect of
mproved prophylaxis strategies, detection methods, or
eightened awareness of DVT over the interval of included
tudies is not entirely known but may influence the current
ncidence of this complication. To minimize this, we lim-
ted our review to series published after 1990, to reflect a
ore modern era of DVT prophylaxis strategies. Second,
he precise location of DVT in NSQIP is not recorded, and
any DVTs may represent upper extremity DVT, whereas
ithin our literature review, we focused on lower extremity
VT alone. Additionally, although uncommon, a superfi-
ial phlebitis that requires anticoagulation, such as one
rotruding into a deep vein, is included in the NSQIP
efinition of DVT. Third, the quality of evidence encoun-
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domized trials or similar high-quality evidence of the inci-
dence of postoperative surveillance of DVT was not
available for each procedure. Thus, our search strategy
included cohort studies to obtain the best estimate of
postoperative DVT. Fourth, although controversial, we
elected to include calf DVTs in determining the “numera-
tor” for the incidence of DVTs in many of our literature
studies. Although treatment for calf DVTs may vary by
practitioner, many current guidelines recommend treat-
ment in high-risk patients because they are associated with
a 20% propagation rate, post-thrombotic syndrome, and
small risk of pulmonary embolism.54 Additionally, due to
the aggregated and de-identified nature of the ACS NSQIP
data, we cannot adjust for variability in postoperative DVT
surveillance programs, or DVT prevention strategies, across
different hospitals. Any underlying variation in prophylaxis
strategies or DVT surveillance could potentially influence any
individual hospital’s rate of DVT. Finally, although our find-
ings that DVT were similar to symptomatic rates were fairly
consistent across procedures, symptomatic DVTs were higher
after amputation than in NSQIP. There is insufficient detail
within the pooled studies to fully explain this finding; how-
ever, it may have been due to low rates of prophylaxis, or the
fact that phlebitic pain or edema may be hard to distinguish
from postoperative pain and swelling after amputation.
In conclusion, our study has illustrated that broad
variation in the rate of postoperative DVT is present in
patients undergoing high-risk surgery, and the manner in
which DVT is diagnosed may explain some of this variation.
NSQIP is an important and broadly visible national QI
program, and findings from NSQIP are widely studied and
quoted.55 Given its national prominence, these findings are
often extrapolated to wide practice settings and used by
policymakers and physicians alike to forge new directions in
quality measurement in healthcare.56 Therefore, to allow a
“level playing field” for accurate comparison, benchmark-
ing, and quality improvement, further details about the
method of detection would make DVT rates reported in
NSQIP more valuable to surgeons, patients, and policy-
makers interested in improving surgical practice.
We would like to thank Yuanyuan Zhao for her assis-
tance with statistical review.
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October 20121051.e1 De Martino et alAppendix A (online only). List of CPT-9 CM used for identification of surgical cases within NSQIPOpen aortic cases 35,102, 35,108, 35,091, 35,103, 35,082, 35,092, 34,830, 34,831, 34,832, 35,631, 35,531, 35,631,
35,560, 35,647, 35,537, 35,538, 35,539, 35,331, 35,537, 35,311
LEB 35,656, 35,556, 35,583, 35,666, 35,566, 35,585, 35,671, 35,571, 35,587
Amputations 27,880, 27,882, 27,590, 27,592, 27,596, 27,594, 27,884
Hip arthroplasty 27,130, 27,125, 27,134, 27,137, 27,138, 27,132
Prostatectomy 55,801, 55,810, 55,812, 55,815, 55,821, 55,831, 55,840, 55,842, 55,845, 55,866
GBP surgery 43,846, 43,847, 43,644, 43,645
CPT-9 CM, Current Procedural Terminology Codes; GBP, gastric bypass; LEB, lower extremity bypass; NSQIP, National Surgical Quality Improvement
Program.
Appendix B (online only). Definitions of DVT variables within ACS NSQIP
Variable Definition
DVT/thrombophlebitis The identification of a new blood clot or thrombus within the venous system, which may be
coupled with inflammation within 30 days of the operation. This diagnosis is confirmed
by a duplex, venogram, or CT scan. The patient must be treated with anticoagulation
therapy and/or placement of a vena cava filter or clipping of the vena cava.
Number of DVT/thrombophlebitis
complications
Number of DVT/thrombophlebitis complications.
Days from operation until DVT/
thrombophlebitis complication
Days from operation until DVT/thrombophlebitis complication.
ACS, American College of Surgeons; CT, computed tomography; DVT, deep vein thrombosis; NSQIP, National Surgical Quality Improvement Program.
Adapted from 2009 ACS-NSQIP Participant User Data File User Guide.
